Massimo Giachetti The U.S. FDA has granted an additional approval for Pfizer’s (NYSE:PFE) antibody-drug conjugate
georgeclerk Pfizer (NYSE:PFE) has entered into a multi-year collaboration with Alloy Therapeutics to develop a
libre de droit A combination of Pfizer (NYSE:PFE) and Astellas’ (OTCPK:ALPMF)(OTCPK:ALPMY) antibody-drug conjugate Padcev (enfortumab
PamelaJoeMcFarlane/iStock via Getty Images Live poultry markets were ordered shut down on Friday in New
JHVEPhoto/iStock Editorial via Getty Images Shares of Bristol-Myers Squibb (NYSE:BMY) traded lower in the premarket
Earnings Call Insights: Pfizer (NYSE:PFE) Q4 2024 Management View CEO Albert Bourla highlighted Pfizer’s strong
georgeclerk Although Pfizer (NYSE:PFE) reiterated 2025 financial guidance issued in December, the midpoints of the
Pfizer press release (NYSE:PFE): Q4 Non-GAAP EPS of $0.63 beats by $0.17. Revenue of $17.8B